uniQure (QURE) director trades; 20,439 shares remain as of 11/04/2025

Accepted by SEC EDGAR 11/06/2025 - 05:01 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

uniQure N.V. (QURE) disclosed that a director executed option exercises and same‑day sales on 11/04/2025 pursuant to a Rule 10b5‑1 trading plan adopted on June 16, 2025.

The director exercised 10,000 options at $7.37, 11,000 at $5.37, and 17,810 at $14.08, then sold equivalent ordinary shares at weighted average prices of $30.36, $30.34, and $30.33, respectively. Following these transactions, the director beneficially owned 20,439 ordinary shares, held directly.

Insider Trade Summary

Exercise and Sale: 38,810 shares ($794K approx. pre-tax spread)

Exercise and Sale 9 txns

Insider Kaye Jack

Role Director

Sold 38,810 shs ($1.18M)

Approx. gross sale proceeds $1.18M

Approx. exercise cost $384K

Approx. pre-tax spread $794K

Share of Position Sold 65.5%

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	10,000	$0.00	$0.00
Exercise	Stock Option (Right to Buy)	11,000	$0.00	$0.00
Exercise	Stock Option (Right to Buy)	17,810	$0.00	$0.00
Exercise	Ordinary Shares	10,000	$7.37	$74K
Sale	Ordinary Shares	10,000	$30.36	$304K
Exercise	Ordinary Shares	11,000	$5.37	$59K
Sale	Ordinary Shares	11,000	$30.34	$334K
Exercise	Ordinary Shares	17,810	$14.08	$251K
Sale	Ordinary Shares	17,810	$30.33	$540K

Holdings After Transaction: Stock Option (Right to Buy) — 0 contracts (Direct); Ordinary Shares — 20,439 shares (Direct)

Holdings Before and After: Stock Option (Right to Buy), 38,810 to 0 contracts (Direct); Ordinary Shares, 20,439 to 20,439 shares (Direct)

Footnotes (7)

1. F1. The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on June 16, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.
2. F2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.20 to $30.79. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. F3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.16 to $30.75. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
4. F4. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.00 to $30.90. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
5. F5. The Stock Option vested 25% on June 30, 2018 and 6.25% quarterly thereafter.
6. F6. The Stock Option vested in full on January 27, 2018.
7. F7. The Stock Option vested in full on June 15, 2023.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did uniQure (QURE) report in this Form 4?

A director exercised stock options and sold the resulting ordinary shares under a Rule 10b5-1 plan.

When did the QURE transactions occur?

All transactions took place on 11/04/2025.

How many options were exercised and at what prices?

Options for 10,000 shares at $7.37, 11,000 at $5.37, and 17,810 at $14.08 were exercised.

At what prices were the shares sold?

Shares were sold at weighted averages of $30.36, $30.34, and $30.33; sales occurred in multiple trades within disclosed ranges.

How many QURE shares does the director own after these trades?

The director beneficially owns 20,439 ordinary shares directly after the reported transactions.

Was a Rule 10b5-1 trading plan used?

Yes. The plan was adopted on June 16, 2025 and the transactions were effected pursuant to it.

What transaction codes appeared on the Form 4?

Code M (option exercise) and code S (sale) were reported.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kaye Jack

(Last) (First) (Middle)

C/O UNIQURE N.V.

PAASHEUVELWEG 25A

(Street)

AMSTERDAM P7 11058BP

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
uniQure N.V. [ QURE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/04/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	11/04/2025		M(1)		10,000	A	$7.37	30,439	D
Ordinary Shares	11/04/2025		S(1)		10,000	D	$30.36(2)	20,439	D
Ordinary Shares	11/04/2025		M(1)		11,000	A	$5.37	31,439	D
Ordinary Shares	11/04/2025		S(1)		11,000	D	$30.34(3)	20,439	D
Ordinary Shares	11/04/2025		M(1)		17,810	A	$14.08	38,249	D
Ordinary Shares	11/04/2025		S(1)		17,810	D	$30.33(4)	20,439	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$7.37	11/04/2025		M(1)			10,000	(5)	06/29/2027	Ordinary Shares	10,000	$0	0	D
Stock Option (Right to Buy)	$5.37	11/04/2025		M(1)			11,000	(6)	01/27/2027	Ordinary Shares	11,000	$0	0	D
Stock Option (Right to Buy)	$14.08	11/04/2025		M(1)			17,810	(7)	06/15/2032	Ordinary Shares	17,810	$0	0	D

Explanation of Responses:

1. The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on June 16, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.20 to $30.79. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.16 to $30.75. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

4. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.00 to $30.90. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

5. The Stock Option vested 25% on June 30, 2018 and 6.25% quarterly thereafter.

6. The Stock Option vested in full on January 27, 2018.

7. The Stock Option vested in full on June 15, 2023.

	/s/ Christian Klemt, Attorney-in-Fact	11/06/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.